Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer

BACKGROUND: The prognostic value of CA19-9 in patients with pancreatic cancer (PC) treated with neoadjuvant therapy has not been well described. METHODS: Pre-treatment CA19-9 levels (with concomitant normal bilirubin level) in patients with localized PC were categorized as normal (≤35), low (36–200)...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:HPB (Oxford)
Asıl Yazarlar: Aldakkak, Mohammed, Christians, Kathleen K, Krepline, Ashley N, George, Ben, Ritch, Paul S, Erickson, Beth A, Johnston, Fabian M, Evans, Douglas B, Tsai, Susan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Ltd 2015
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4571763/
https://ncbi.nlm.nih.gov/pubmed/26255895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hpb.12448
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller